Blisibimod anthera
WebReductions in SLE autoantibodies and B cells, and increases in complement C3 and C4 were observed with blisibimod. Blisibimod was well-tolerated. The most common adverse events were upper respiratory tract infection, … WebAug 28, 2024 · HAYWARD, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced top line final data from the extension of the randomized, double-blind, placebo controlled, Phase 2 BRIGHT-SC study of blisibimod in 58 patients with IgA nephropathy (IgAN).
Blisibimod anthera
Did you know?
WebDec 15, 2014 · Anthera is developing blisibimod, a selective inhibitor of B-cell activating factor (BAFF), to explore its clinical utility in various autoimmune diseases including …
WebSep 14, 2015 · Anthera will regain all worldwide rights for blisibimod without cost No patients were enrolled in the BRIGHT-SC study or any other clinical study in Japan Zenyaku is required to continue... WebAug 9, 2024 · HAYWARD, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that blisibimod has received orphan …
WebApr 11, 2024 · Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the T.. Anthera Pharmaceuticals, Inc. announced that it expects to receive $15 million in fundi.. Anthera Pharmaceuticals, Inc. Announces Top Line Final Data from Phase 2 BRIGHT-SC Stud.. WebJan 23, 2013 · Anthera observed a statistically significant drop in proteinuria in patients treated with blisibimod in the PEARL-SC trial, providing clinical evidence supporting the …
WebNov 15, 2016 · Anthera will continue to analyze the results of the trial in consultation with lupus specialists to determine the future of the blisibimod lupus program, including the …
WebAug 16, 2016 · Anthera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening … t4 line 20WebAnthera Pharmaceuticals, Inc. Message board - Online Community of active, educated investors researching and discussing Anthera Pharmaceuticals, Inc. Stocks. brazier\u0027s 2yWebAnthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced positive trends from the Week 48 analysis of the Phase 2 BRIGHT-SC proof-of-concept study in 57 patients with IgA nephropathy. The effects of blisibimod versus placebo were assessed through at least the 48 week time point in all patients in the BRIGHT-SC study. t4 line 26WebAug 4, 2015 · The purpose of this study is to evaluate the clinical efficacy of blisibimod as measured by a composite responder index in subjects who, despite corticosteroid use, continue to have seropositive, clinically-active Systemic Lupus Erythematosus (SLE) as defined by SELENA-SLEDAI score ≥10, and positive for anti-double stranded DNA and … brazier\\u0027s 2zWebAug 14, 2024 · The U.S. Food and Drug Administration (FDA) has granted orphan drug status to the investigative therapy blisibimod for the treatment of immunoglobulin A nephropathy (IgAN), according to Anthera Pharmaceuticals, the drug’s developer. t4 line 29WebSep 27, 2013 · Blisibimod (B-mod) is a selective peptibody antagonist of the BAFF cytokine. In other words, it binds to BAFF, preventing it from being used in the creation of … brazier\\u0027s 2yWebFeb 3, 2014 · A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy: Study Start Date : October 2014: Estimated Primary Completion Date : October 2016: ... Anthera Pharmaceuticals: ClinicalTrials.gov Identifier: NCT02052219 Other Study ID … t4 line 28